May 7, 2025

Notice of Biohit Oyj’s Annual General Meeting

Biohit Oyj Stock Exchange Release May 7, 2025 at 2:00 pm local time (EEST)

Biohit Oyj shareholders are invited to attend the company’s Annual General Meeting to be held on Wednesday, June 4, 2025 starting at 2:00 pm at the Katajanokan kasino, Karimo hall, for which the address is Laivastokatu 1, 00160 Helsinki. The reception of registered participants and the distribution of voting papers at the meeting venue will start at 1:00 pm.

A. Matters on the agenda of the Annual General Meeting

1.    Opening of the meeting

2.    Calling the meeting to order

3.    Election of persons to inspect the Minutes and supervise the counting of votes

4.    Recording the legality of the meeting

5.    Recording the attendance at the meeting and the list of votes

6.    Presentation of the Financial Statements, the Report of the Board of Directors and the Auditor’s Report for 2024

7.    Adoption of the Financial Statements

The Board of Directors proposes that the Annual General Meeting adopts the annual accounts. The Auditor of the Company has supported the adoption of the annual accounts.

8.    Resolution on the use of the profit shown on the Balance Sheet and on dividend payment / Board’s proposal for distributions of profit

The Board of Directors proposes to the Annual General Meeting that the result for the financial period ended on 31st of December 2024 be recorded in the profit and loss account.

The parent company’s distributable funds (unrestricted equity) on 31 December 2024 are EUR 8 222 057,08, of which the period net profit is EUR 2 406 631,87. The Board of Directors proposes to the Annual General Meeting that no dividend be paid for the financial year.

9.    Resolution on the discharge of the members of the Board of Directors and the CEO from liability

10.  Resolution on the number and remuneration of the members of the Board of Directors

Shareholders representing more than 50% of the voting rights conferred by all company’s shares have announced their intention to propose to the Annual General Meeting that the number of Board members be confirmed at five (5). These shareholders have announced their intention to propose to the Annual General Meeting that remuneration is paid to the Board members and the Chairman as follows: EUR 2,500 per month (previously EUR 2,500 per meeting) to the Chairman and EUR 2,000 per month (previously EUR 2,000 per meeting) to other Board members.

11.  Election of Board Members

Shareholders representing more than 50% of the voting rights conferred by all company’s shares have announced their intention to propose to the Annual General Meeting that the following persons be elected to the Company’s Board of Directors until the end of the next Annual General Meeting: Liu Feng, Kalle Härkönen, Lea Paloheimo, Vesa Silaskivi and Osmo Suovaniemi. All candidates have given their consent to the election. More information on member candidates is available on May 7 2025 on the company website at https://sijoittajat.biohithealthcare.com/en/investors/corporate_governance/annual_general_meeting_2025.

12.  Addressing the Remuneration Report of the Company’s governing bodies

The Board of Directors proposes that the Remuneration Report of the Company’s governing bodies for 2024 be approved. The resolution is advisory in accordance with the Finnish Limited Liability Companies Act.

The Remuneration Report is available on the Company’s website at https://sijoittajat.biohithealthcare.com/en/investors/corporate_governance/remuneration.

13.  Resolution on the remuneration of the Auditor

The Board of Directors proposes to the Annual General Meeting that the Auditor to be elected be remunerated according to an invoice approved by the Company.

14.  Election of the Auditor

Shareholders representing more than 50% of the voting rights conferred by all company’s shares have announced that Authorized Public Accountants PricewaterhouseCoopers Oy be elected as Auditors until the end of the next Annual General Meeting. PricewaterhouseCoopers Oy has informed the Company that Authorized Public Accountant Tiina Puukkoniemi is going to act as the auditor with the principal responsibility.

15.  Authorizing the Board of Directors to decide on the issuance of shares and on the issuance of option rights and other special rights entitling to shares

The Board of Directors proposes to the Annual General Meeting that the Annual General Meeting authorises the Board to decide on the issuance of shares and the issuance of option rights and other special rights entitling to shares referred to in Chapter 10, section 1 of the Limited Liability Companies Act in one or more instalments as follows:

The maximum number of new Series B shares to be issued pursuant to the authorisation is 500 000 (including shares to be issued based on the special rights), which corresponds to approximately 4,09 % of the company’s all existing Series B shares.

The authorisation includes the Board of Directors’ entitlement to decide on all terms and conditions regarding the share issue and the issue of special rights. The share issue and the issue of special rights entitling to shares can occur in derogation from the pre-emptive subscription right of the shareholders (directed issue).

The authorisation remains valid for two (2) years from the resolution of the Annual General Meeting.

16.  Closing of the meeting

B.   Documents for the General Meeting

The proposals for the decisions on the matters on the agenda of the Annual General Meeting as well as this notice are available on Biohit Oyj’s website at https://sijoittajat.biohithealthcare.com/en/investors/corporate_governance/annual_general_meeting_2025. The annual report, the group’s annual report, the report of the Board of Directors, and the Auditor’s report as well as the remuneration report and policy of Biohit Oyj are available on the aforementioned website as from 7 May 2025 at the latest. The proposals for decisions and other documents mentioned above will also be available for inspection at the General Meeting.

The minutes of the meeting will be available on the aforementioned website as from 9 June 2025 at the latest.

C.   Instructions for the participants at the Annual General Meeting

1.    The right to participate and registration

Shareholders who on the Annual General Meeting record date of Thursday 22 May 2025 are registered in the Company’s shareholder register maintained by Euroclear Finland Oy have the right to participate in the Annual General Meeting. Any shareholder whose shares are registered on his/her personal Finnish book-entry account is registered in the company’s shareholder register.

Registration for the meeting will begin on 12 May 2025 at 10.00 am EEST. A shareholder entered in the Company's shareholder register, who wishes to participate in the Annual General Meeting, must register latest on Friday 30 May 2025 at 4.00 pm EEST, by which time the registration needs to be received. It is possible to register for the General Meeting:

a)    through the Company’s website at https://sijoittajat.biohithealthcare.com/en/investors/corporate_governance/annual_general_meeting_2025. If the shareholder is an individual, electronic registration requires strong electronic authentication, which takes place either with a Finnish bank ID or a Finnish mobile certificate.

If the shareholder is a legal person, electronic registration requires either strong electronic authentication, or the book-entry account number and Business ID of the shareholder; or

b)    by email to yhtiokokous@biohit.fi

When registering for the meeting, the following details shall be provided: the shareholder’s name, personal identity number or Business ID, address, telephone number as well as the name of any proxy representative or assistant to be used, and the personal identity number of the proxy representative. The personal data given by shareholders to Biohit Oyj will only be used in connection with the General Meeting and for processing the necessary registrations.

The shareholder, their representative or proxy must be able to prove their identity and/or right of representation at the meeting, where necessary.

2.    Shareowners with nominee-registered shares

Shareowners with nominee-registered shares have the right to participate in the Annual General Meeting on the basis of the shares held on the record date of the Annual General Meeting, i.e. 22 May 2025, that would give them the right to be included in the Company's shareholder register maintained by Euroclear Finland Oy. Attendance also requires that the shareholder is temporarily entered in the Company’s shareholder register maintained by Euroclear Finland Oy by 10:00 am EEST on Friday 30 May 2025 at the latest. For shareholders with nominee-registered shares, this is considered registration for the Annual General Meeting. Any changes in the ownership of shares that occur after the record date of the General Meeting do not affect the right to participate in the General Meeting or the number of votes a shareholder may cast.

Shareholders with nominee-registered shares are encouraged to request without delay the necessary instructions concerning temporary registration with the Company’s shareholder register, issuing proxy documents, and registration for the Annual General Meeting from their custodian bank. The account management organization of the custodian bank must register a shareholder with nominee-registered holdings, who wants to participate in the Annual General Meeting, temporarily into the Company’s Shareholder Register at the latest by the time stated above. Further information is also available on the Company's website at https://sijoittajat.biohithealthcare.com/en/investors/corporate_governance/annual_general_meeting_2025.

3.    Proxy representatives and powers of attorney

A shareholder may participate in the Annual General Meeting by way of proxy representation. A proxy representative shall produce a dated proxy document or otherwise in a reliable manner demonstrate their right to represent the shareholder at the Annual General Meeting. When a shareholder participates in the Annual General Meeting by means of several proxy representatives, representing the shareholder with shares in different book-entry accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the Annual General Meeting.

Possible proxy documents should be delivered by regular mail to Yhtiökokous, Laippatie 1, 00880 Helsinki or by e-mail to yhtiokokous@biohit.fi before the end of the registration period. In addition to delivering the documents of proxy, the shareholder or his/her proxy shall ensure that they are registered for the General Meeting in the manner described above in this notice.

4.    Other information

The language used in the meeting shall be Finnish.

A shareholder has the right to ask questions referred to in Chapter 5, Section 25 of the Finnish Limited Liability Companies Act with respect to the matters to be considered at the Meeting.

Any changes in the ownership of shares that occur after the record date of the General Meeting do not affect the right to participate in the General Meeting or the number of votes a shareholder may cast.

The information on the Annual General Meeting required by the Finnish Limited Liability Companies Act and the Securities Market Act is available on the Company’s website at https://sijoittajat.biohithealthcare.com/en/investors/corporate_governance/annual_general_meeting_2025.

On 7 May 2025, the date of the notice of the Annual General Meeting, the share capital of Biohit Oyj consists of a total of 15 185 593 shares. The shares are divided into Series A and Series B. The total number of Series A shares is 2 975 500 producing a total of 59 510 000 votes, while the total number of Series B is 12 210 093 producing a total of 12 210 093 votes.

Helsinki, 7 May 2025

Biohit Oyj
The Board of Directors

Additional information:

Chairperson of the Board Vesa Silaskivi, Biohit Oyj
puh. +358 9 773 861
investor.relations@biohit.fi
www.biohit.fi

Biohit Oyj in Brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohit.fi